ライフサイエンスコーパス: HLA antigen

1 e HLA mismatched (4.6+/-1.2 of the six major HLA antigens).

2 ing or a sibling with a mismatch of a single HLA antigen.

3 unrelated donors were mismatched for >/= one HLA antigen.

4 enic stimuli for antibody production against HLA antigens.

5 ersing AHR mediated by Ab specific for donor HLA antigens.

6 odies directed to either class I or class II HLA antigens.

7 same donor reduces the exposure to different HLA antigens.

8 valences and encourage laboratories to split HLA antigens.

9 pient pairs were discordant for one to three HLA antigens.

10 demonstrated specificity to mismatched donor HLA antigens.

11 rn following exposure to single and multiple HLA antigens.

12 s related to a reduced expression of class I HLA antigens.

13 ed in level of antibody reactivity to intact HLA antigens.

14 ested against iBeads coated only with intact HLA antigens.

15 ion of a transplant candidate's unacceptable HLA antigens.

16 0% of them showed antibodies directed to non-HLA antigens.

17 at inhibited Th alloreactivity against graft HLA antigens.

18 owerful in identifying epitopes shared among HLA antigens.

19 matching to exclude donors with unacceptable HLA antigens.

20 ated beads, possibly because it detected non-HLA antigens.

21 f they are directed against mismatched donor HLA antigens.

22 d blood that were mismatched for two or more HLA antigens.

23 ic Ab (DSA) for one or more mismatched donor HLA antigens.

24 might have against human leukocyte antigen (HLA) antigens.

25 independent of the well-known association of HLA antigen (2-digit specificity) MMs with kidney graft

26 patients who developed "new" antibody to the HLA antigen (3.9%-8.6%) of the tetramer after transplant

27 eived cord blood that was mismatched for one HLA antigen (34 patients) or two antigens (116 patients)

28 ts with antibodies against beta2m-free HC of HLA antigens (88%, P=0.0056).

29 rmal antibody values as well as frequency of HLA antigen alleles were compared between patient and co

30 rols were tested for celiac disease-specific HLA antigen alleles; 13 of 22 TG6 IgA seropositive indiv

31 Registry data were used for derivation of HLA antigen and haplotype frequencies in a 1996 report.

32 ll and by method of identifying unacceptable HLA antigens and crossmatch techniques.

33 m 31 donors known to have antibodies against HLA antigens and from 16 antibody-negative controls were

34 ear evidence of improved definition of rarer HLA antigens and haplotypes, particularly among minoriti

35 with a self-eplet shared between immunizing HLA antigens and HLA antigens of the antibody producer.

36 xperimental filtration removed antibodies to HLA antigens and inhibited the accumulation of lipid pri

37 nsplantation by serologic typing for class I HLA antigens and low-resolution molecular typing for cla

38 correlation between the number of mismatched HLA antigens and the number of V beta elements involved.

39 filtrate EBV+ tumors bearing the appropriate HLA antigens and thereafter induce targeted regressions

40 e (HMO) and U937 on the levels of FcgammaRs, HLA antigens, and monokines, elutriated HMOs and U937 ce

41 s, detection of antibodies (Abs) against non-HLA antigens, and subjective scoring.

42 ssion have been found to underlie changes in HLA antigen, APM component, costimulatory molecule and t

43 These non-HLA antigens are classified as either alloantigens, such

44 HLA antigens are polymorphic proteins expressed on donor

45 e impact when antibodies to both HLA and non-HLA antigens are present pretransplant.

46 ents may become sensitized to donor-specific HLA antigens as a result of previous antigenic exposures

47 Of a possible 74,514 individual HLA antigen assignments, 2.7% were discrepant.

48 frequency of discrepancies of the individual HLA antigen assignments.

49 Repeated mismatched HLA antigens between first and second transplant may be

50 where patients were considered sensitized to HLA antigens but did not have antibody before transplant

51 ic B cells in patients who are sensitized to HLA antigens but lacking detectable antibody abrogates a

52 because the donors expressed a diversity of HLA antigens, but was largely a result of the substrate-

53 th American white NIH blood donors typed for HLA antigens by the same molecular technique (HLA-DR15,

54 ion of unacceptable human leukocyte antigen (HLA) antigens by most advanced solid phase immunoassays

55 adaveric kidneys based on broader classes of HLA antigens, called cross-reactive groups (CREG).

56 d immune response factors, most specifically HLA antigen class I-restricted HIV-specific CD8 T cells,

57 somal regulation of tumor-associated peptide/HLA antigen complexes, and yield possible therapeutic so

58 Although alloantibodies against HLA antigens contribute to the pathogenesis of CAI, allo

59 entify a list of acceptable and unacceptable HLA antigens, could improve the access of highly sensiti

60 Some patients sensitized to HLA antigens do not have antibody present in serum speci

61 esence of serum anti-HLA antibodies to donor HLA antigens (donor-specific antibodies) and serum MHC c

62 A birth cohort of children with HLA antigen-DQB1-conferred susceptibility to type 1 diab

63 and that centers review the UNOS listing of HLA antigen equivalences and encourage laboratories to s

64 The United Network for Organ Sharing HLA antigen equivalences were applied to the data.

65 in the regulatory mechanisms, which control HLA antigen expression and/or abnormalities in one or mo

66 nt cells as well as their role in changes in HLA antigen expression by malignant cells have been revi

67 igenetic modifications underlying changes in HLA antigen expression in malignant cells have been disc

68 Abnormalities in HLA antigen expression in malignant cells, which range i

69 enetic events associated with alterations in HLA antigen expression may be clinically relevant as, in

70 dy titers against Y chromosome-encoded minor HLA antigens fell and remained low, whereas titers again

71 Only 1 cellular target HLA antigen for the serum was expressed in 238 cases, 20

72 LA-A2 as a marker for the release of soluble HLA antigens from the donor, we established that recipie

73 ve cancer risk as outcome, not be focused on HLA antigen genetic markers, and be published in English

74 dated gliadine peptide and TG6 and performed HLA antigen genotyping in 150 consecutive patients with

75 gen heavy chain(s), mutations, which inhibit HLA antigen heavy chain transcription or translation, de

76 2)m) synthesis, loss of the gene(s) encoding HLA antigen heavy chain(s), mutations, which inhibit HLA

77 ypically matched kidneys with fewer than six HLA antigens identified had an 89% 1-year graft survival

78 globulin (Ig)G antibody to one or more donor HLA antigens in 49 patients treated with alternate-day,

79 t sex-mismatched, Y chromosome-encoded minor HLA antigens in association with chronic GVHD.

80 de novo antibodies against mismatched donor HLA antigens in kidney transplantation.

81 valence, and importance of antibodies to non-HLA antigens in late allograft injury are poorly charact

82 ght result in alloimmunisation stimulated by HLA antigens in seminal or cervicovaginal fluid.

83 cess, which appears to be, at least in part, HLA antigen independent.

84 study addressed the question how mismatched HLA antigens induce specific antibodies in context with

85 Sensitization against HLA antigens is a growing problem in the field of pediat

86 hogenesis of CAI, alloantibodies against non-HLA antigens likely contribute as well.

87 Partially HLA antigen-matched allogeneic hematopoietic stem cell (

88 with severe Wiskott-Aldrich syndrome lacking HLA antigen-matched related or unrelated HSC donors (age

89 Engineered T cells caused cytotoxicity in HLA/antigen-matched tumors and induced IFN-gamma product

90 toimmunity directed at kidney-expressed, non-HLA antigens may also participate.

91 out differences in immunogenicity of various HLA antigens may help guide donor selection and identify

92 e a sequential kidney transplant, a repeated HLA antigen mismatch was not associated with a detriment

93 enal transplantation, functional status, and HLA antigen mismatch.

94 mandatory sharing of kidneys that have zero HLA antigens mismatched with specific patients on the wa

95 an male who received an ABO-compatible, five HLA antigen-mismatched kidney-pancreas transplant from a

96 UCB grafts (93%) were 1-2 HLA antigen-mismatched with the recipient and contained

97 ched related donors, 3.79 (P < .0001) with 2-HLA-antigen-mismatched related donors, 2.11 (P < .0001)

98 eference group, were 2.43 (P < .0001) with 1-HLA-antigen-mismatched related donors, 3.79 (P < .0001)

99 s in treatment failure were less striking: 1-HLA-antigen-mismatched relatives, 1.22 (P = not signific

100 elatives, 1.22 (P = not significant [NS]); 2-HLA-antigen-mismatched relatives, 1.81 (P < .0001); HLA-

101 hed unrelated donors, 1.39 (P = .002); and 1-HLA-antigen-mismatched unrelated donors, 1.63 (P = .002)

102 nrelated donors, and 3.33 (P < .0001) with 1-HLA-antigen-mismatched unrelated donors.

103 e specificities than can be accounted for by HLA antigen mismatches.

104 independent of the well-known association of HLA antigen MMs with graft survival.

105 including patient and donor risk factors and HLA antigen MMs.

106 ncluding the effect of noninherited maternal HLA antigens (NIMA) and double-unit cord blood transplan

107 of kidneys from siblings expressing paternal HLA antigens not inherited by the recipient (86 percent

108 of kidneys from siblings expressing maternal HLA antigens not inherited by the recipient than in reci

109 rvival is higher when the donor has maternal HLA antigens not inherited by the recipient than when th

110 sibling donors bearing maternal or paternal HLA antigens not inherited by the recipient.

111 e recipient than when the donor has paternal HLA antigens not inherited by the recipient.

112 ival advantage of grafts expressing maternal HLA antigens not inherited by the recipient.

113 y, loss of antibody to donor and third-party HLA antigens occurred in 89% and 19%, respectively, of p

114 comparisons were discrepant in at least one HLA antigen of six possible antigens per phenotype.

115 66%) B cells and a previous mismatch for the HLA antigen of the tetramer.

116 , and matching of CMV serological status and HLA antigens of donor and recipient.

117 t shared between immunizing HLA antigens and HLA antigens of the antibody producer.

118 evidence of at least moderate antibodies to HLA antigens on cord units originally selected for trans

119 pient pairs who differed by no more than one HLA antigen or allele, high-resolution class II HLA typi

120 -recipient pairs who were mismatched for two HLA antigens or alleles, high-resolution typing was used

121 ents with ESRD who were highly sensitized to HLA antigens (panel reactive antibody [PRA] > or =50% mo

122 IDs belonged to arachidonic acid pathway and HLA antigen processing pathway.

123 allocation policy and racial differences in HLA antigen profiles, using a Cox model for the time fro

124 While many of these non-HLA antigens remain poorly defined, the principal antige

125 ated serum concentrations of soluble class I HLA antigens (S-HLA-I) with HLA allotypes in 82 unrelate

126 ells, and not as obviously influenced by the HLA antigen(s) on the stimulator cells.

127 The presence of mismatched HLA antigens seemed to affect the reconstitution kinetic

128 whether mismatched human leukocyte antigen (HLA) antigens should be avoided in subsequent renal tran

129 lloimmunized both to neutrophil-specific and HLA antigens, suggesting that the transfusion of these p

130 preimplantation genetic diagnosis (PGD) and HLA antigen testing.

131 LAMatchmaker can identify certain mismatched HLA antigens that are zero-triplet mismatches to the pat

132 and anatomic roadmap of the most likely non-HLA antigens that can generate serological responses aft

133 des that share cryptic determinants with the HLA antigens that initially sensitized the patient.

134 riability in the immunogenicity of different HLA antigens that is impacted by the presence or absence

135 Testing System (KATS), that predicts class I HLA antigens that would be both "unacceptable" and "acce

136 ddition, using actual patients' unacceptable HLA antigens, the number of compatible donors that would

137 ural antibodies to the heavy chains (HCs) of HLA antigens, the preparations were then tested against

138 .6% of the population) present no mismatched HLA antigens to be recognized by their offspring's immun

139 uring patient workup for transplantation and HLA antigens to which a patient is sensitized then be av

140 8-year study, our analysis was based on the HLA antigens used for organ exchange (11 A locus antigen

141 at acquired tolerance to disparate unrelated HLA antigens was achieved.

142 t of IgG antibody directed to donor-specific HLA antigens was extremely uncommon and, furthermore, ha

143 patients with granulocytes matched only for HLA antigens will not be effective.

144 atches where available, or alternatively, no HLA antigens with more than five immunogenic triplet mis

145 ization of host alloreactivity to individual HLA antigens with sufficient sensitivity and specificity

146 ation of HLAMatchmaker identified additional HLA antigens with zero-triplet mismatches for 27 patient